Trial Profile
Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Grifols
- 04 Feb 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 04 Feb 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.
- 13 Aug 2020 Planned End Date changed from 1 Apr 2020 to 1 Dec 2022.